The far-reaching impact of antimicrobial resistance

Clinical Infectious Diseases

Volumn 45, Issue SUPPL. 2, 2007, Pages

  Rehm, Susan J ^a   Weber, J Todd ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ANTIBIOTIC AGENT; OSELTAMIVIR; POLYMYXIN DERIVATIVE; RIMANTADINE; TRICLOSAN;

ANTIBIOTIC RESISTANCE; CLINICAL PRACTICE; CONFERENCE PAPER; DRUG APPROVAL; DRUG EFFICACY; GRAM NEGATIVE BACTERIUM; HAND WASHING; HEALTH CARE SYSTEM; HUMAN; INFECTION; NONHUMAN; NUCLEIC ACID AMPLIFICATION; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

ANIMALS; BIRDS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG RESISTANCE, MULTIPLE, FUNGAL; DRUG RESISTANCE, MULTIPLE, VIRAL; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; INFLUENZA A VIRUS; INFLUENZA IN BIRDS; INFLUENZA, HUMAN;

EID: 34548264113     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/519260     Document Type: Conference Paper

References (12)

1. Moberg CL. René Dubos: a harbinger of microbial resistance to antibiotics. Microb Drug Resist 1996; 2:287-97.
2. Rahal JJ. Novel antibiotic combinations against infections with almost completely resistant Pseudomonas aeruginosa and Acinetobacter species. Clin Infect Dis 2006; 43(Suppl 2):S95-9.
3. Li J, Nation RL, Turnidge JD, et al. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis 2006; 6:589-601.
4. Bright RA, Shay DK, Shu B, Cox NJ, Klimov AI. Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. JAMA 2006; 295:891-4.
5. Beigel JH, Farrar J, Han AM, et al. Avian influenza A (H5N1) infection in humans. N Engl J Med 2005; 353:1374-85.
6. Procop GW. Molecular diagnostics for the detection and characterization of microbial pathogens. Clin Infect Dis 2007; 45(Suppl 2):S99-111 (in this supplement).
7. Valiquette L, Cossette B, Garant M-P, Diab H, Pépin J. Impact of a reduction in the use of high-risk antibiotics on the course of an epidemic of Clostridium difficile-associated disease caused by the hypervirulent NAP1/027 strain. Clin Infect Dis 2007; 45(Suppl 2):S112-21 (in this supplement).
8. Miller MA. Clinical management of Clostridium difficile-associated disease. Clin Infect Dis 2007; 45(Suppl 2):S122-8 (in this supplement).
9. Olofsson SK, Cars O. Optimizing drug exposure to minimize selection of antibiotic resistance. Clin Infect Dis 2007; 45(Suppl 2):S129-36 (in this supplement).
10. Aiello AE, Larson EL, Levy SB. Consumer antibacterial soaps: effective or just risky? Clin Infect Dis 2007; 45(Suppl 2):S137-47 (in this supplement).
11. Lloyd DH. Reservoirs of antimicrobial resistance in pet animals. Clin Infect Dis 2007; 45(Suppl 2):S148-52 (in this supplement).
12. Powers JH. Increasing the efficiency of clinical trials of antimicrobials: the scientific basis of substantial evidence of effectiveness of drugs. Clin Infect Dis 2007; 45(Suppl 2):S153-62 (in this supplement).